However, we found that the PPAR-α agonists decreased hyperglycemia (from 273.4 mg/dL to 159.4 mg/dL), A1C (from 12.9% to 5.6%), and glucose tolerance in DM2-treated rats (Figure 1B–E). This evidence concerns the gene PPARA and Hyperglycemia.